News

Christian Lienhardt Discusses the Newly Launched TB-PACTS Database

Christian Lienhardt, from WHO, discusses the launch of TB-PACTS, the new data-sharing platform for TB clinical trials. This marks the beginning of an exciting new tool in the fight against TB. Announced on April 18th, TB-PACTS combines clinical trial data from Critical Path Institute (C-Path), the Special Programme for Research and Training in Tropical Diseases (TDR), TB Alliance, and St. George’s, University of London. Hosted on the C-PATH website, it strives to standardize all Phase III tuberculosis clinical trial data. According to the website, “researchers can access and analyze data in aggregate, or filter and view individual patient-level data from the REMoxTB, RIFAQUIN and OFLUTUB clinical trials”.

TB-PACTS, which stands for TB-Platform for Aggregation of Clinical TB Studies, is accessible to researchers after registering an online application. The website informs users it may take up to 4 weeks for the application to be processed. Once registered users are able and encouraged to contribute data as well. The site assures users that they retain ownership of their data and that the platform is secure.

As Dr. Lienhardt discusses, having a larger database improves and refines the ability to analyze the data. It provides an increased sample size, an opportunity to perform analysis of specific populations, and an increased likelihood of finding commonalities that were not picked up in the single trials.

Related Links

TB-PACTS Website

Christian Lienhardt Discusses TB-PACTS

TB-PACTS Press Release

More News
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...
5 Jun 2019
**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019** The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new...